The effect of extracorporeal shock wave therapy in acute traumatic spinal cord injury on motor and sensory function within 6 months post-injury: a study protocol for a two-arm three-stage adaptive, prospective, multi-center, randomized, blinded, placebo-controlled clinical trial.
Extracorporeal shock wave therapy
Off-label use
Spinal cord injuries
Treatment outcome
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
received:
11
03
2021
accepted:
07
03
2022
entrez:
2
4
2022
pubmed:
3
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
The pathological mechanism in acute spinal cord injury (SCI) is dual sequential: the primary mechanical lesion and the secondary injury due to a cascade of biochemical and pathological changes initiated by the primary lesion. Therapeutic approaches have focused on modulating the mechanisms of secondary injury. Despite extensive efforts in the treatment of SCI, there is yet no causal, curative treatment approach available. Extracorporeal shock wave therapy (ESWT) has been successfully implemented in clinical use. Biological responses to therapeutic shock waves include altered metabolic activity of various cell types due to direct and indirect mechanotransduction leading to improved migration, proliferation, chemotaxis, modulation of the inflammatory response, angiogenesis, and neovascularization, thus inducing rather a regeneration than repair. The aim of this clinical study is to investigate the effect of ESWT in humans within the first 48 h after an acute traumatic SCI, with the objective to intervene in the secondary injury phase in order to reduce the extent of neuronal loss. This two-arm three-stage adaptive, prospective, multi-center, randomized, blinded, placebo-controlled study has been initiated in July 2020, and a total of 82 patients with acute traumatic SCI will be recruited for the first stage in 15 participating hospitals as part of a two-armed three-stage adaptive trial design. The focused ESWT (energy flux density: 0.1-0.19 mJ/mm The application of ESWT activates the nervous tissue regeneration involving a multitude of various biochemical and cellular events and leads to a decreased neuronal loss. ESWT might contribute to an improvement in the treatment of acute traumatic SCI in future clinical use. ClinicalTrials.gov NCT04474106.
Sections du résumé
BACKGROUND
BACKGROUND
The pathological mechanism in acute spinal cord injury (SCI) is dual sequential: the primary mechanical lesion and the secondary injury due to a cascade of biochemical and pathological changes initiated by the primary lesion. Therapeutic approaches have focused on modulating the mechanisms of secondary injury. Despite extensive efforts in the treatment of SCI, there is yet no causal, curative treatment approach available. Extracorporeal shock wave therapy (ESWT) has been successfully implemented in clinical use. Biological responses to therapeutic shock waves include altered metabolic activity of various cell types due to direct and indirect mechanotransduction leading to improved migration, proliferation, chemotaxis, modulation of the inflammatory response, angiogenesis, and neovascularization, thus inducing rather a regeneration than repair. The aim of this clinical study is to investigate the effect of ESWT in humans within the first 48 h after an acute traumatic SCI, with the objective to intervene in the secondary injury phase in order to reduce the extent of neuronal loss.
METHODS
METHODS
This two-arm three-stage adaptive, prospective, multi-center, randomized, blinded, placebo-controlled study has been initiated in July 2020, and a total of 82 patients with acute traumatic SCI will be recruited for the first stage in 15 participating hospitals as part of a two-armed three-stage adaptive trial design. The focused ESWT (energy flux density: 0.1-0.19 mJ/mm
DISCUSSION
CONCLUSIONS
The application of ESWT activates the nervous tissue regeneration involving a multitude of various biochemical and cellular events and leads to a decreased neuronal loss. ESWT might contribute to an improvement in the treatment of acute traumatic SCI in future clinical use.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04474106.
Identifiants
pubmed: 35365190
doi: 10.1186/s13063-022-06161-8
pii: 10.1186/s13063-022-06161-8
pmc: PMC8973563
doi:
Banques de données
ClinicalTrials.gov
['NCT04474106']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Subventions
Organisme : Allgemeine Unfallversicherungsanstalt
ID : NA
Informations de copyright
© 2022. The Author(s).
Références
Radiology. 2015 Aug;276(2):553-61
pubmed: 25906184
Ortop Traumatol Rehabil. 2007 Sep-Oct;9(5):467-83
pubmed: 18026067
Nat Rev Mol Cell Biol. 2014 Dec;15(12):825-33
pubmed: 25355507
Neurol India. 2017 Sep-Oct;65(5):1033-1034
pubmed: 28879892
Exp Neurol. 1996 Apr;138(2):261-76
pubmed: 8620925
Int J Surg. 2015 Dec;24(Pt B):124-30
pubmed: 26291028
Cochrane Database Syst Rev. 2012 Jan 18;1:CD001046
pubmed: 22258943
Spinal Cord. 2012 May;50(5):365-72
pubmed: 22270188
Brain Res. 2003 Apr 25;970(1-2):238-41
pubmed: 12706267
Int J Surg. 2015 Dec;24(Pt B):147-53
pubmed: 26612525
J Neurotrauma. 2017 Dec 15;34(24):3362-3371
pubmed: 28683592
PLoS One. 2012;7(2):e32037
pubmed: 22384132
Wound Repair Regen. 2012 Jul-Aug;20(4):456-65
pubmed: 22642362
J Med Life. 2014;7 Spec No. 3:127-32
pubmed: 25870710
PLoS One. 2014 Aug 05;9(8):e103982
pubmed: 25093816
Prog Neurobiol. 2014 Mar;114:25-57
pubmed: 24269804
Cardiovasc Res. 2016 Feb 1;109(2):331-43
pubmed: 26676850
Brain. 2005 Feb;128(Pt 2):356-64
pubmed: 15634734
Lancet. 2002 Feb 23;359(9307):696-700
pubmed: 11879884
Injury. 2005 Jul;36 Suppl 2:B13-26
pubmed: 15993113
Inflammation. 2014 Feb;37(1):65-70
pubmed: 23948864
Phys Ther. 1987 Feb;67(2):206-7
pubmed: 3809245
Spinal Cord. 2017 Oct;55(10):886-890
pubmed: 28534496
J Spinal Cord Med. 2004;27(1):41-6
pubmed: 15156936
J Bone Joint Surg Am. 2010 Mar;92(3):583-9
pubmed: 20194316
Exp Neurol. 2020 Jun;328:113251
pubmed: 32087252
Exp Neurol. 2012 Aug;236(2):363-70
pubmed: 22575596
Arch Phys Med Rehabil. 2006 Jan;87(1):15-9
pubmed: 16401432
J Neurosurg. 2014 Dec;121(6):1514-25
pubmed: 25280090
J Spinal Cord Med. 2016 May;39(3):255-64
pubmed: 26864974
Curr Pain Headache Rep. 2011 Jun;15(3):215-22
pubmed: 21387163
Spinal Cord. 2008 Feb;46(2):86-95
pubmed: 17909559
Spinal Cord. 1996 Sep;34(9):560-4
pubmed: 8883191
J Neurosurg. 2000 Jul;93(1 Suppl):1-7
pubmed: 10879751
Dev Med Child Neurol. 2006 Jan;48(1):64-73
pubmed: 16359597
J Orthop Trauma. 2017 Sep;31 Suppl 4:S14-S23
pubmed: 28816871
Spinal Cord. 2014 Feb;52(2):110-6
pubmed: 23439068
Rehabilitacion (Madr). 2022 Jan-Mar;56(1):1-10
pubmed: 33966896
J Am Heart Assoc. 2015 Oct 27;4(10):e002440
pubmed: 26508745
NeuroRehabilitation. 2014 Jan 1;35(2):235-44
pubmed: 24990026
Yonsei Med J. 2013 Jul;54(4):1020-5
pubmed: 23709440
Int Wound J. 2009 Feb;6(1):11-21
pubmed: 19291111
J Orthop Trauma. 2010 Mar;24(3):133-41
pubmed: 20182248
Int J Surg. 2015 Dec;24(Pt B):179-83
pubmed: 26454164
Arch Phys Med Rehabil. 2007 Sep;88(9):1185-92
pubmed: 17826466
J Neurosurg Spine. 2016 Dec;25(6):745-755
pubmed: 27367940
Spinal Cord. 2007 Mar;45(3):206-21
pubmed: 17179972
Arch Phys Med Rehabil. 2016 Oct;97(10):1610-9
pubmed: 27109331
Spinal Cord. 2010 Mar;48(3):207-13
pubmed: 19786977
Exp Neurol. 1997 Sep;147(1):159-71
pubmed: 9294413
Int Rev Neurobiol. 2013;109:85-98
pubmed: 24093607
Spinal Cord. 2006 Sep;44(9):523-9
pubmed: 16389270
Clin Rehabil. 1999 Oct;13(5):373-83
pubmed: 10498344
J Neurophysiol. 2003 Jan;89(1):416-26
pubmed: 12522190
Spine (Phila Pa 1976). 2009 Nov 1;34(23):E841-7
pubmed: 19927090